Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hydrogensulfate salt of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation

A technology of fulminate bisulfate and crystal form, which is applied in the field of platelet aggregation inhibitors, and can solve problems affecting drug stability, dissolution rate, bioavailability, and ability to influence

Inactive Publication Date: 2011-05-25
SANDOZ AG
View PDF11 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, these polymorphs are different solid forms that possess the same molecular formula of the compound that constitutes the crystal, but they may have different advantageous physical properties that may directly affect the handling and / or processing of the drug substance (e.g., flow properties) and capabilities of the drug product (e.g. flow) and may directly affect drug product stability, dissolution and bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hydrogensulfate salt of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
  • Hydrogensulfate salt of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
  • Hydrogensulfate salt of 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0041] In the preparation method of crystalline form I of prasugrel hydrogensulfate, due to the cooling of the solution, crystals of crystalline form I of prasugrel hydrogensulfate can grow after adding seeds. This is because at higher temperatures the seeds may dissolve and prasugrel bisulfate may thus remain in solution.

[0042] When the temperature of the solution has reached a value at which the seeds remain crystalline for a sufficient time, for example about 30° C. or less, seeds are added to promote crystallization. The seeds may be pure Form I of prasugrel bisulphate or may be prasugrel bisulphate seeds prepared as described in Example 1 of the present application.

[0043] The seed crystals obtained from Example 1 were a mixture of amorphous prasugrel hydrogen sulfate and crystalline form I of prasugrel hydrogen sulfate.

[0044] After the temperature has been lowered to the desired temperature, the reaction mixture is brought to that temperature so that crystalliza...

Embodiment 1

[0108] Embodiment 1: the preparation of seed crystal

[0109] 1 ml of ethyl acetate was added to 1.2 equivalents (18 μl) of concentrated sulfuric acid (95-97%), and the solution was stirred at room temperature. After addition of 100.0 mg prasugrel, a sticky coagulated mass of amorphous prasugrel bisulfate was obtained. The solvent was removed and the solid was dried under vacuum at room temperature for 2 hours. This material was added to a solution of 1.2 equivalents (18 μl) of concentrated sulfuric acid (95-97%) and 100.0 mg of prasugrel in 800 μl of acetone. The solution was stored without stirring at -25°C for about 20 hours to grow white to off-white crystals. The solvent was removed and the crystals were vacuum dried at room temperature to obtain a mixture of amorphous prasugrel hydrogen sulfate and crystalline form I of prasugrel hydrogen sulfate.

[0110] It should be noted that the time required to obtain seeds in the initial experiments was significantly longer, ar...

Embodiment 2

[0112] Example 2: Preparation of Form I of Prasugrel Hydrogen Sulfate

[0113] 250.0 mg of prasugrel and 1.2 equivalents (44 μl) of concentrated sulfuric acid (95-97%) were dissolved in 2 ml of acetone at 40°C. The solution was cooled slowly to room temperature and seeded with prasugrel bisulfate obtained in Example 1. After stirring at room temperature for 17.5 hours, the precipitate was filtered off, washed with acetone and dried under vacuum at room temperature to obtain 199.1 mg (63% yield) of crystalline form I of prasugrel hydrogensulfate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to crystalline form I of Prasugrel hydrogensulfate. A process for the preparation of these salts, pharmaceutical compositions comprising the salts and the use of the salts as a pharmaceutical, in particular as a blood platelet aggregation inhibitor are also described. Seed crystals which can be employed in the above mentioned process as well as a process for their preparation are also disclosed.

Description

technical field [0001] The present invention relates to the production of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrogensulfate Form I. Also described are processes for the preparation of said salts, pharmaceutical compositions comprising said salts and the use of said salts as medicaments, in particular as platelet aggregation inhibitors. Seed crystals applicable in the above methods and their preparation methods are also disclosed. Background of the invention [0002] Prasugrel, 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine, is Thienopyridine derivatives and as antiplatelet drugs. Platelet activation and subsequent platelet aggregation play an important role in the pathogenesis of cardiovascular disease. Previous clinical studies have shown that prasugrel is effective orally and produces rapid and sustained effective antiplatelet and antithrombotic effects through platelet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D495/04A61K31/4365A61P7/02
CPCC07D495/04A61P7/02
Inventor A·霍特J·威瑟尔A·皮希勒
Owner SANDOZ AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com